A researcher explains the rationale for and goals of her investigations of blood-based biomarkers for Alzheimer’s disease specifically in women.
An early-career Cleveland Clinic researcher has devised a multipronged strategy that integrates advanced computational and experimental approaches to dementia research. The work has attracted $16 million in external grant funding in 2023 alone.
A new project is using tools from sleep research, neuroimaging, and blood and CSF biomarker analysis to study sex-specific influences of sleep and circadian rhythm disruption on neurocognitive decline.
New research aims to determine whether differences in the blood-based proteome between men and women with Alzheimer’s can help identify biomarkers to improve care for women with the disease.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Elevations in plasma triglyceride/HDL cholesterol ratio and plasma apolipoprotein A1 were associated with worse cognitive outcomes in a retrospective study of people with mild cognitive impairment or Alzheimer’s disease dementia.
New NIH-funded research combines analysis of blood-brain barrier changes with detailed characterization of AD-associated immunity changes. The aim is insights that lead to new avenues of therapy.
Application of the novel framework has identified the dyslipidemia medication gemfibrozil as a candidate drug to reduce Alzheimer’s disease risk.
Two brain health experts discuss what the prominent study results mean for the amyloid hypothesis and what to expect next in both clinical practice and the research landscape.
A combination of pharmacoepidemiologic studies and Mendelian randomization genetic analysis revealed preferential protection in Black but not white individuals. The findings support ongoing studies of telmisartan for Alzheimer’s, particularly in racially diverse cohorts.
Many aspects of Alzheimer’s differ between the sexes. In this Q&A, an expert in the disease among women discusses recent research insights and where the field is likely headed.